Brokerages expect that EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) will post earnings of ($0.41) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for EyeGate Pharmaceuticals’ earnings. EyeGate Pharmaceuticals posted earnings of ($0.43) per share during the same quarter last year, which would indicate a positive year over year growth rate of 4.7%. The firm is expected to issue its next earnings report on Wednesday, May 5th.
On average, analysts expect that EyeGate Pharmaceuticals will report full year earnings of ($1.47) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($1.36). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover EyeGate Pharmaceuticals.
EyeGate Pharmaceuticals (NASDAQ:EYEG) last released its quarterly earnings results on Thursday, March 25th. The specialty pharmaceutical company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The firm had revenue of $0.01 million for the quarter.
Shares of EyeGate Pharmaceuticals stock traded up $0.04 during midday trading on Friday, reaching $4.31. 12,086 shares of the company’s stock traded hands, compared to its average volume of 77,853. The company has a market cap of $30.59 million, a price-to-earnings ratio of -2.14 and a beta of 1.27. The company’s 50 day simple moving average is $5.22 and its 200 day simple moving average is $4.91. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.76 and a current ratio of 3.76. EyeGate Pharmaceuticals has a 52 week low of $3.20 and a 52 week high of $8.18.
About EyeGate Pharmaceuticals
EyeGate Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease.
Read More: Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EyeGate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyeGate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.